GRI Bio Reports $3.4 Million Net Loss in Q3 2025, Faces Financial Challenges

GRI Bio, Inc. reported a net loss of $3.4 million for the third quarter of 2025, compared to a loss of $2.1 million in the same period of 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $9.3 million, up from $6.3 million in the prior year. Total operating expenses for the third quarter increased to $3.4 million from $2.1 million year-over-year, driven primarily by a rise in research and development costs, which reached $1.8 million, up from $1.1 million. General and administrative expenses also rose to $1.6 million from $1.0 million, reflecting increased personnel costs and public company expenses.

In terms of financial position, GRI Bio's total assets decreased to $4.8 million as of September 30, 2025, down from $5.7 million at the end of 2024. The company's cash and cash equivalents also fell to $4.1 million from $5.0 million over the same period. Current liabilities increased significantly to $2.8 million from $1.7 million, primarily due to higher accounts payable and accrued expenses. The accumulated deficit reached $49.0 million, reflecting the ongoing financial challenges faced by the company since its inception.

Strategically, GRI Bio has focused on advancing its lead product candidate, GRI-0621, an oral inhibitor for treating severe fibrotic lung diseases. The company has received regulatory clearances to initiate a Phase 2a biomarker study for GRI-0621 in the U.S., U.K., and Australia, with enrollment completed in July 2025. Preliminary data from the study suggest a potential anti-fibrotic effect, and topline results are expected by the end of November 2025. Additionally, GRI Bio has been actively raising capital through various offerings, including a recent $4.0 million public offering in April 2025 and an At The Market Offering that has generated approximately $5.9 million in net proceeds.

Operationally, GRI Bio's employee headcount has increased as the company expands its research and development efforts. The company has also engaged in several financing activities to support its operations, including the issuance of common stock and warrants. As of September 30, 2025, GRI Bio had sold 1.68 million shares under its ATM Offering at a weighted average price of $3.67 per share. However, the company acknowledges the need for additional funding to sustain its operations and continue its clinical development programs, indicating a substantial reliance on future capital raises to maintain its business activities.

Looking ahead, GRI Bio anticipates continued operating losses as it invests in the development of its product candidates. The company believes its existing cash will be sufficient to fund operations into the first quarter of 2026, but it faces significant uncertainty regarding its ability to secure additional financing. The management has expressed concerns about the company's ability to continue as a going concern if it cannot raise the necessary capital, which could lead to reductions in spending or even the cessation of operations.